Synairgen (LON:SNG) Reaches New 12-Month Low – What’s Next?

Synairgen plc (LON:SNG) shares hit a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 1.81 ($0.02) and last traded at GBX 2 ($0.02), with a volume of 3416760 shares changing hands. The stock had previously closed at GBX 1.99 ($0.02).

Synairgen Stock Performance

The business’s fifty day simple moving average is GBX 3.60 and its 200-day simple moving average is GBX 3.96. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 6.77. The firm has a market capitalization of £4.03 million, a PE ratio of -66.67 and a beta of -2.23.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).